Expression of matrix metalloproteinases in liver tissues with nonalcoholic steatohepatitis

World Chinese Journal of Digestology

Volumn 10, Issue 11, 2002, Pages 1257-1260

  Meng, Er Hong ^a   Zhao, Jing Min ^a   Wang, Song Shan ^a   Liu, Wang Xia ^a   Liu, Ping ^a   Zhou, Guang De ^a   Zhang, Tai He ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MEMBRANE TYPE 2 MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FATTY LIVER; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LIVER CELL; LIVER FIBROSIS; MESENCHYME; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STELLATE CELL;

EID: 0036857952     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Shivakumar C, Geoffrey CF. Eiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:37
2. Helena CP, Amelia B, Maria EC, Miguel CM. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepato Gastroenterol 2001;48:87-90
3. Wojtowicz-Praga SM. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75
4. Velasco G, Cal S, Merlos SA. Human MT6-matrix metalloprotinase: Identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000;15:877-882
5. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-384
6. Massova I, kotra LP, Fridman R. Matrix metalloproteinase: Structures, evolution and diversification. FASEB J 1998;12:1075
7. Miloni S, Herbst H, Schuppan D. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994;144:528
8. Authur MJ. Degradation of Matrix proteins in liver fibrosis. Pathol Res Pract 1994;190:825-33
9. Takahara T, Furui K, Yata Y. Dural expression of matrix metalloproteinase-2 and membrane typel-matrix metalloproteinase in fibrotic human liver. Hepathology 1997;26:1521
10. Preaux AM, Mallat A, Nhieu JT, D'Ortho MP,Hembry RM, Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999;30:944-950
11. Alcolado R, Arthur MJP, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997;92:103-112
12. Kasahara A, Hayashi N, Mochizuki K. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relatiobship to interferon response. J Hepatol 1997;26:574-583
13. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinase and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Bio 2000; 113:443-453
14. Theret N, Musso O, L'Helgoualc'h A. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interaction with hepatocytes. Am J Pathol 1997;150:551
15. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999;107:38-44
16. Arthur MJ, Fibrosis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000;279: G245-249
17. Fillmore HL, VanMeter TE, Broaddus WC. Membrane-type matrix metalloproteinase(MT-MMPs):expression and function during glioma invasion. J Neurooncol 2001;53:187-202
18. Theret N, Musso O, L'Helgoualc'h A, Campion JP, Clement B. Differential expression and origin of membrane-type1 and 2 matrix metalloproteinase(MT-MMPs) in association MMP2 activation in injured human liver. Am J Pathol 1998;153:945
19. Reeves HL, Burt AD, Wood S. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlate with the severity of steatosis. J Hepatol 1996;25:677-683
20. Arthur MJ. Fibrosis and altered matrix degradation. Digestion 1998;12:66
21. D'Ortho MP, Will H, Atkinson S. Membrane-type Matrix metalloproteinase 1 and 2 exhibit broad-spectum proteolytic capacities comparable to many matrix metalloproteinase. Eur J Biochem 1997;250:751-757
22. Sato H, Takino T, Okada Y. A matrix metalloproteinase expressed on the surface of invasive cells tumour. Nature 1994; 370:61-65
23. Cao J, Rehemtulla A, Bahou W. Membrane-type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996;271:30174- 30180
24. 3-MMPs with and without transmembrane domain. J Biol Chem 1997;272: 9749-9754
25. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271:9135-9140
26. Hiraoka N, Allen E, Apel IJ. Matrix metalloproteinase regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95:365-377
27. 1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-384
28. Yu M, Sato H, Seiki M. Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 1995;55:3272-3277
29. Lohi J, Kehti K, Westermarck J. Regulation of membrane-type 1 matrix metalloproteinase expression by growth factors and phorbal 12-myristate 13-acetate. Eur J Biochem 1996;239:239-247
30. Polette M, Gilles G, Marchand V. Induction of membrane-type matrix metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron-mocroscopy. Int J Cancer 1996;68:565-570
31. Takahara T, Furui K, Funaki J. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995;21:787-795
32. Ludwig J, Viggiano T, Mcgill D. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Pro 1980;55:434-438